CD133 expression in patients with peripheral neuroblastic tumor: a systematic review

Introduction: Neuroblastoma is known as one of the most common solid tumors in children, which is recently under the investigation for the expression of CD133, a marker of cancer stem cells. Revealing the prognostic value of CD133 marker expression is important in predicting the outcome and survival...

Full description

Bibliographic Details
Main Authors: Hedieh Nazarzadeh, Yavar Shams Hojati, Reza Nazarzadeh
Format: Article
Language:English
Published: Mashhad University of Medical Sciences 2015-09-01
Series:Reviews in Clinical Medicine
Subjects:
Online Access:http://rcm.mums.ac.ir/pdf_4716_22c561b6a78511782b48f56d3f8e3382.html
_version_ 1818149782787457024
author Hedieh Nazarzadeh
Yavar Shams Hojati
Reza Nazarzadeh
author_facet Hedieh Nazarzadeh
Yavar Shams Hojati
Reza Nazarzadeh
author_sort Hedieh Nazarzadeh
collection DOAJ
description Introduction: Neuroblastoma is known as one of the most common solid tumors in children, which is recently under the investigation for the expression of CD133, a marker of cancer stem cells. Revealing the prognostic value of CD133 marker expression is important in predicting the outcome and survival of neuroblastoma patients. In this systematic review, we aimed to review the studies on association between CD133 expression and other peripheral neuroblastic tumor prognostic factors.Methods: PubMed was searched for the relevant articles. No time and language limitation were included in our search strategy. Data regarding the patients’ number and age, tumor stage, histology and CD133 expression were extracted.Results: Overall, only 4 relevant articles were retrieved. One articles revealed the positive association between CD133 expression in neuroblastoma samples and its resistance to chemotherapy treatment. Three of the included articles showed the positive relation between CD133 expression rate and tumor stage progression. Two of the included studies revealed much worse survival of the neuroblastoma patients with more expression of CD133.Discussion: Based on included studies, CD133 expression is positively related with poor outcome prognosis in patients, more advanced tumor stage, shorter disease-free survival and overall survival. Conclusion: Although the expression of CD133 has shown increasing trend by advancing the neuroblastoma tumor stage, more studies with larger sample size are needed to accurately reveal the relation.
first_indexed 2024-12-11T13:12:31Z
format Article
id doaj.art-ff0c68c790464fcb94511a3791e9190b
institution Directory Open Access Journal
issn 2345-6256
2345-6892
language English
last_indexed 2024-12-11T13:12:31Z
publishDate 2015-09-01
publisher Mashhad University of Medical Sciences
record_format Article
series Reviews in Clinical Medicine
spelling doaj.art-ff0c68c790464fcb94511a3791e9190b2022-12-22T01:06:09ZengMashhad University of Medical SciencesReviews in Clinical Medicine2345-62562345-68922015-09-01241641674716CD133 expression in patients with peripheral neuroblastic tumor: a systematic reviewHedieh Nazarzadeh0Yavar Shams Hojati1Reza Nazarzadeh2Department of Pathology, Ghaem hospital, Mashhad University of Medical Sciences, Mashhad, IranDepartment of surgery, Ghaem hospital, Mashhad University of Medical Sciences, Mashhad, Iran.Department of pediatric surgery, Mashhad University of Medical Sciences, Mashhad, Iran.Introduction: Neuroblastoma is known as one of the most common solid tumors in children, which is recently under the investigation for the expression of CD133, a marker of cancer stem cells. Revealing the prognostic value of CD133 marker expression is important in predicting the outcome and survival of neuroblastoma patients. In this systematic review, we aimed to review the studies on association between CD133 expression and other peripheral neuroblastic tumor prognostic factors.Methods: PubMed was searched for the relevant articles. No time and language limitation were included in our search strategy. Data regarding the patients’ number and age, tumor stage, histology and CD133 expression were extracted.Results: Overall, only 4 relevant articles were retrieved. One articles revealed the positive association between CD133 expression in neuroblastoma samples and its resistance to chemotherapy treatment. Three of the included articles showed the positive relation between CD133 expression rate and tumor stage progression. Two of the included studies revealed much worse survival of the neuroblastoma patients with more expression of CD133.Discussion: Based on included studies, CD133 expression is positively related with poor outcome prognosis in patients, more advanced tumor stage, shorter disease-free survival and overall survival. Conclusion: Although the expression of CD133 has shown increasing trend by advancing the neuroblastoma tumor stage, more studies with larger sample size are needed to accurately reveal the relation.http://rcm.mums.ac.ir/pdf_4716_22c561b6a78511782b48f56d3f8e3382.htmlCancer stem cellsCD133Neuroblastoma
spellingShingle Hedieh Nazarzadeh
Yavar Shams Hojati
Reza Nazarzadeh
CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
Reviews in Clinical Medicine
Cancer stem cells
CD133
Neuroblastoma
title CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
title_full CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
title_fullStr CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
title_full_unstemmed CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
title_short CD133 expression in patients with peripheral neuroblastic tumor: a systematic review
title_sort cd133 expression in patients with peripheral neuroblastic tumor a systematic review
topic Cancer stem cells
CD133
Neuroblastoma
url http://rcm.mums.ac.ir/pdf_4716_22c561b6a78511782b48f56d3f8e3382.html
work_keys_str_mv AT hediehnazarzadeh cd133expressioninpatientswithperipheralneuroblastictumorasystematicreview
AT yavarshamshojati cd133expressioninpatientswithperipheralneuroblastictumorasystematicreview
AT rezanazarzadeh cd133expressioninpatientswithperipheralneuroblastictumorasystematicreview